The Memo: O2matic Automating Oxygen Therapy in Hospital and Home Care

Under the direction of CEO Marie-Louise Little, O2matic is advancing a more precise and automated approach to oxygen therapy for patients who need oxygen, replacing manual flow adjustments with closed-loop titration designed to keep blood oxygen saturation within a target range. With CE-marked systems spanning hospital and home use, the company is working to reduce clinician workload, improve patient safety, and modernize a treatment modality that still relies heavily on manual processes. As the company looks ahead, a central focus for O2matic in 2026 is establishing a clear pathway into the U.S. market.

Origin Story

O2matic was founded in 2017 with a clear and urgent premise. Oxygen therapy could be done better.

“The founders created the company back in 2017, and really, it was a consideration that we must be able to do oxygen therapy better, and we must be able to remove the manual impact of that and make it more automated,” Little said.

Despite oxygen being one of the most widely used therapies in medicine, dosing has historically relied on manual flow adjustments that struggle to keep patients within a safe saturation range. Too much oxygen can be toxic. Too little can impair breathing and tissue oxygenation. Levels can fluctuate rapidly, yet clinical staff often adjust flow rates only intermittently.

O2matic’s first CE-marked product reached the market during the COVID-19 period, when respiratory illness and oxygen demand surged worldwide. That moment reinforced the relevance of the company’s core vision: automated, closed-loop oxygen therapy that continuously adapts to a patient’s needs.

Little joined O2matic initially as a board member representing investor T&W Medical before stepping into the CEO role. Her background spans executive leadership, operations, commercial strategy, and medical device investing.

“What I really enjoy is making a difference in a company,” she said. “Seeing where the value is, and moving that company toward both commercial success and something that will make a difference for patients and for investors.”

The Current Landscape

Oxygen therapy today is largely based on a method developed 100 years ago. Treatment is traditionally performed by manually reading a flowmeter and adjusting oxygen delivery by turning a pressure regulator. In hospital settings, medical staff may adjust oxygen flow up to 30 times per patient per day, placing significant strain on already limited resources. According to O2matic, patients receive the correct oxygen dosage less than half of the time.

This imprecision has meaningful clinical and economic consequences. Globally, an estimated 500 million patients are treated with supplemental oxygen. 

“Most of those patients have chronic respiratory disease, like COPD or fibrosis,” Little said. “But there are also acute care situations. Patients who are transported, patients who have been operated on. There are many moments where patients need supplemental oxygen.”

Despite its importance, oxygen therapy has not benefited from the same level of automation seen in areas like insulin delivery or cardiac monitoring.

“We don’t often think about oxygen as something that can be harmful in the wrong dose,” Little said. “Once you understand that oxygen is toxic at too high levels, and harmful at too low levels, it becomes obvious to use an automated system that doses oxygen correctly.”

Inside the Innovation

At the core of O2matic’s technology is a closed-loop system that continuously measures oxygen saturation and automatically adjusts oxygen flow in real time.

“Our system is in a closed loop together with an off-the-shelf blood saturation device. That information is given to our system, which then directs what level of oxygen should be provided to that patient,” Little explained. 

This architecture underpins both of the company’s primary products.

O2matic PRO 100, designed for hospital use, continuously monitors oxygen saturation and pulse via a pulse oximeter and automatically adjusts oxygen delivery. The system also includes alarm functions that notify clinicians if a patient’s condition requires attention. Clinical data shows significant reductions in time spent in hyperoxia and severe hypoxemia, along with improved oxygen targeting compared to manual treatment.

O2matic HOT 100, the home-based system, extends the same closed-loop principle into long-term oxygen therapy. Rather than requiring patients to wear sensors continuously, HOT 100 relies on scheduled measurement sessions throughout the day. The system manages oxygen delivery between sessions and transmits treatment data to a central platform, allowing healthcare professionals to remotely monitor patients and make informed decisions.

“At home, we are able to treat patients remotely because we obtain data coming into our platform,” Little said. “A nurse can sit in her clinic and see the data from her patients at home. That flow of data from home into the hospital or clinic is really key.”

Both systems connect to existing oxygen sources such as concentrators or cylinders and support integration with additional devices via Bluetooth. The platform is designed to be extensible, supporting future applications in transport, emergency care, and military environments.

Progress and Milestones

O2matic has been commercially active in Europe since 2021, with a strong initial focus on clinical validation. The PRO 100 is MDR approved and in use across multiple European markets, while the HOT 100 has completed early evaluations in Denmark and is preparing for broader rollout.

Looking ahead, O2matic is sharpening its commercial focus as it prepares for broader adoption across Europe. 

At the same time, O2matic is advancing its platform into new clinical settings. In December 2025, the company announced a collaboration with the University of Colorado Anschutz School of Medicine as part of a U.S. Department of Defense-funded research initiative. The AURORA Project will evaluate O2matic’s autonomous oxygen therapy technology in prehospital emergency care, building on the previously completed SAVE-O2 AI study, a 300-patient, four-site U.S. trial with data expected in the first quarter of 2026.

The company is also preparing for U.S. market entry, with FDA approval targeted for 2027.

O2matic is currently closing its Series A round, with plans to initiate the next financing following key U.S. data readouts. Longer term, the company sees significant opportunity in leveraging the data generated by its platform to support earlier intervention, remote care, and broader respiratory disease management.

“The respiratory field is still immature compared to cardiology or diabetes,” Little said. “We really believe this should be the next area of focus. There are so many patients suffering, and that is not likely to change.”

Join Us at LSI USA ‘26

Little has been selected to present at LSI USA ‘26 next March 16th–20th in front of hundreds of global medical technology companies. Join us in welcoming her to the event in Dana Point, CA, where she will share the latest updates on O2matic’s technology and development.